Nasdaq

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Hosted on MSN

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce the ...
KFGO

Moderna, Merck’s skin cancer vaccine shows sustained benefit in long-term follow-up

Moderna and Merck said on Tuesday their experimental vaccine for a serious ‍type of skin cancer, when used with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial based on ...
Seeking Alpha

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...